Skip to main content

Immune Response BioPharma, Inc.

Home
Drug Discovery
Press Releases
Investor Relations
Royalties
Stock Information
Executive Team
Scientific Board
Clinical Trials
REMUNE Vaccine
REMUNE Rx Co-pay Card
REMUNE FULL PRESCRIBING
REMUNEX Vaccine
Remune Pediatric
RemuneVax Vaccine
NeuroVax Vaccine
NeurOral
RAVAX Vaccine
RAVAX II Vaccine
Zorcell Vaccine
DermaVax
Immunereszumab
Sepsicillin
Rare Diseases
Alliances
Vaccines Direct
Partnering
Bio Defense
Immune Response Hospital
Orchestra Therapeutics
Research Donations
About Us
Corporate Filings
Corporate ByLaws
Transfer Agent
Employment
Events
Webcast
Contact Us
Email Alerts
Member Login
Site Map
Immune Response BioPharma, Inc.TM      (C) Copyright 2010-2017



REMUNEX IR103 VACCINE Next Generation HIV/AIDS Vaccine

                                                                                

Principal Investigator

Dr. William Cameron

CTN 203 IR103-111  PHASE II STUDY REMUNE + AMPLIVAX

A Phase I/II safety and immunogencity study of a combination of whole-killed HIV-1 antigen and Amplivax, administered with or without IFA, in HIV-1 infected Participants

http://www.hivnet.ubc.ca/clinical-studies/trial-results-2/ctn-203/

Objective:

This trial set out to determine the optimal dose and formulation of Remune, an experimental therapeutic HIV vaccine in individuals on HAART. The study compared four treatment groups to determine which combinations and doses were best able to generate high levels of efficient HIV-specific immune responses.

The study had four objectives:

1. The safety of immunization using IR103-Remune (HIV-1 antigen in IFA— a water and mineral oil mixture that helps to stimulate the immune system—and Amplivax administered intramuscularly (injected into the muscles).

2. The safety of immunization using IR104-Remune, a combination of Amplivax with HIV-1 antigen (without IFA) administered subcutaneously (into the skin).

3. To assess which dose of Amplivax plus Remune or HIV-1 antigen, in either formulation, is best capable of generating HIV-specific immune responses.

4. To measure changes in CD4 counts in the different treatment groups.

 

Study design

This was a Phase I/II (early stage), randomized, single-blind (either the researcher or the participant is unaware of the nature of the administered treatment), controlled, comparative study. The trial was conducted over 52 weeks at three clinical sites; one in Canada, and two in the UK.

A total of 180 participants were randomized into four treatment groups. Groups one and four had a combined total of 80 individuals who were receiving HAART-inclusive of NNTRI, a class of antiretroviral drug that inhibits the action of reverse transcriptase, and had an undetectable viral load. Groups two and three were each comprised of 50 individuals who had no more than seven days of antiretroviral treatment at any time prior to study entry (antiretroviral-naïve), with a viral load between 1,000 and 60,000 copies/ml.

 

Study population

All participants were eighteen-years of age and older, male or non-pregnant females and had a CD4 count of at least 300 cells/mm3.

 

Results

The combination of Remune with Amplivax was well tolerated with no serious adverse events reported. Changes in the body’s immune system caused by the combination were dose dependent with the maximum effect seen in patients treated with Remune plus 1.0 of Amplivax.

 

Conclusion

The study results provide evidence of safety and tolerance and support further evaluation of this combination as a therapeutic HIV vaccine.






Immune Response BioPharma, Inc. TM                             
Copyright (C) 2010-2017         All Rights Reserved    www.immuneresponse.net